Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Phenylpiracetam | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 100-300 mg/day divided into 1-2 doses | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning or early afternoon; avoid evening use due to stimulant effects. Take with or without food. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Use sparingly — tolerance develops rapidly. Best cycled 2 weeks on, 2 weeks off, or reserved for acute-need situations. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | moderate_human | moderate_human |
Atypical dopamine reuptake inhibitor with additional phenethylamine-like stimulatory properties. Increases the density of acetylcholine, NMDA, GABA, and dopamine receptors in the brain. The phenyl group addition to the piracetam backbone enables blood-brain barrier penetration at 20-60x greater potency than piracetam, with added psychostimulant and cold-tolerance properties.
100-300 mg/day divided into 1-2 doses
Morning or early afternoon; avoid evening use due to stimulant effects. Take with or without food.
Use sparingly — tolerance develops rapidly. Best cycled 2 weeks on, 2 weeks off, or reserved for acute-need situations.
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →